Moderna and Pfizer-BioNTech began trials in March for their vaccines for kids under 12. The results are expected to be made public in the fall.
Health
Lewiston-Auburn remains a COVID-19 hot spot, data suggests
A total of 23 new COVID-19 cases were reported over the past two weeks.
Q&A: Is the delta variant a threat to me? Should I wear a mask again?
Those who are fully vaccinated are well protected, but experts say masks may be advisable for some people in some situations.
Maine expanding opioid treatment during wave of overdose deaths
Gov. Janet Mills says at Maine’s third Opioid Response Summit that isolation caused by the pandemic and resulting mental health challenges contributed to more substance use.
Surgeon general urges U.S. fight against COVID misinformation
U.S. Surgeon General Vivek Murthy is urging technology companies, health care workers and everyday Americans to do more to stop the spread of misinformation about COVID-19 and vaccines.
In medical breakthrough, scientists turn paralyzed man’s thoughts into sentences on computer screen
A California team is developing a device to decode brain waves that normally control the vocal tract, the tiny muscle movements of the lips, jaw, tongue and larynx that form each consonant and vowel.
Maine COVID-19 counts inch higher, with 5 deaths and 40 new cases
The Maine CDC is expecting to see a greater impact of the delta variant in the coming weeks and continues to encourage vaccination as the best form of protection.
The risks of COVID-19 to children under 12 remain low, even as vaccine awaits approval
All pandemic-era mask requirements and other restrictions became recommendations, including in school and child care settings, this month as Maine’s civil state of emergency came to an end.
Maine is exception, but U.S. COVID-19 cases rise again, doubling over 3 weeks
Parts of the country are running up against deep vaccine resistance, while the highly contagious mutant version of the coronavirus that was first detected in India is accounting for an ever-larger share of infections.
FDA chief calls for investigation into review of controversial new Alzheimer’s drug
It’s the latest fallout over last month’s approval of Aduhelm, an expensive and unproven therapy that the agency OK’d against the advice of its own outside experts.